-
公开(公告)号：EP3028703A4
公开(公告)日：2017-01-04
申请号：EP14832281
申请日：2014-07-29
发明人： ISHIDA HIROSHI , MOTOSAWA KEIICHI , MIURA YUSUKE , NAKAI RYUICHIRO , OKADA RYOKO , TAKAHASHI YUICHI
IPC分类号： A61K31/517 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61P11/00 , A61P19/02 , A61P35/00 , A61P43/00 , C07D401/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/052 , C07D491/056 , C07D498/04 , C07D519/00
CPC分类号： C07D401/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D475/00 , C07D487/04 , C07D491/052 , C07D491/056 , C07D498/04 , C07D519/00
摘要： A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n 1A represents 0 or 1; n 2A and n 3A may be the same or different, and each represents 1 or 2; R 0A represents optionally substituted aryl or the like; R 2A represents a hydrogen atom or the like; R 3A represents an optionally substituted aromatic heterocyclic group or the like; X 1A , X 2A , X 3A and X 4A each represent CH or the like; Y 1A represents CH 2 or the like; Y 2A represents N or the like; and L A represents CH 2 or the like) .
摘要翻译： 提供Wnt信号传导抑制剂，其包含作为活性成分的由下式（IA）表示的稠环杂环化合物或其药学上可接受的盐等：（其中n 1A表示0或1; n 2A和n 3A可以相同或不同，各自表示1或2; R 0A表示任选取代的芳基等; R 2A表示氢原子等; R 3A表示任选取代的芳族杂环基等 X 1A，X 3A，X 4A各自表示CH等，Y 1A表示CH 2等，Y 2A表示N等，LA表示CH 2等）。
-
公开(公告)号：EP3083625A1
公开(公告)日：2016-10-26
申请号：EP14815843.9
申请日：2014-12-19
发明人： HARRISON, Timothy , TREVITT, Graham , HEWITT, Peter Robin , O'DOWD, Colin Roderick , BURKAMP, Frank , WILKINSON, Andrew John , SHEPHERD, Steven D. , MIEL, Hugues
IPC分类号： C07D487/04 , C07D519/00 , A61K31/519 , A61P35/00 , C07D487/14
CPC分类号： C07D487/04 , C07D475/00 , C07D487/14 , C07D519/00
摘要： The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
摘要翻译： 本发明涉及用作Wee-1激酶活性抑制剂的化合物。 本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗癌症的方法和治疗癌症的方法。
-
3.发明公开DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF 有权DIHYDROPTERIDINONDERIVATE，工艺用于生产和医药用途
公开(公告)号：EP2481739A4
公开(公告)日：2013-02-27
申请号：EP10818228
申请日：2010-09-14
发明人： TANG PENG CHO , ZHANG NONG , ZHANG BAOLEI , WANG WEIMIN , ZHENG HAO , WU LIN
IPC分类号： C07D475/00 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/00 , C07D519/00
CPC分类号： C07D475/00 , C07D519/00
-
4.发明授权VERFAHREN ZUR HERSTELLUNG VON ANNELIERTEN PIPERAZIN-2-ON DERIVATEN SOWIE ZWISCHENPRODUKTE DES VERFAHRENS 有权用于生产异形ANNE哌嗪-2-酮衍生物，该过程的中间产物
公开(公告)号：EP1819706B1
公开(公告)日：2012-09-19
申请号：EP05823799.1
申请日：2005-11-29
发明人： DURAN, Adil , LINZ, Guenter
IPC分类号： C07D475/00
CPC分类号： C07D475/00
-
公开(公告)号：EP2185559A1
公开(公告)日：2010-05-19
申请号：EP08786733.9
申请日：2008-08-01
发明人： LINZ, Guenter , SIEGER, Peter , SCHMID, Rolf , GOEPPER, Stefan
IPC分类号： C07D475/00 , A61K31/519 , A61P35/00
CPC分类号： C07D475/00
摘要： The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N- [trans-4- [4- (cyclopropylmethyl) - 1-piperazinyl] cyclohexyl] -4- [[(7R) -7-ethyl-5, 6. 7, 8 - tetrahydro - 5 -methyl - 8 - (1 -methylethyl) - 6 - oxo - 2 - pteridinyl] amino] - 3 -methoxy -benz amide of structure (I), to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.
摘要翻译： 本发明涉及二氢奎尼酸衍生物的结晶形式，即游离碱N- [反式-4- [4-（环丙基甲基）-1-哌嗪基]环己基] -4 - [[（7R）-7 （I）的5-乙基-5,6,7,8-四氢-5-甲基-8-（1-甲基乙基）-6-氧代-2-蝶啶基]氨基] -3-甲氧基 - 苯甲酰胺至 其制造方法及其在药物组合物中的用途。
-
6.发明公开TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION 审中-公开TRIHYDROCHLORIDFORMEN一个DIHYDROPTERIDINON衍生物及其制造方法
公开(公告)号：EP1984367A1
公开(公告)日：2008-10-29
申请号：EP07704397.4
申请日：2007-02-07
发明人： GRAUERT, Matthias , LINZ, Guenter , SCHMID, Rolf , SIEGER, Peter
IPC分类号： C07D475/00 , A61K31/19
CPC分类号： C07D475/00
摘要： The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1- piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6- oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.
-
7.发明公开NEUE 6-FORMYL-TETRAHYDROPTERIDINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL U.A. GEGEN KREBS 有权新的6甲酰基tetrahydropteridines，生产与应用，药物方法U.A. 对抗癌症
公开(公告)号：EP1776363A1
公开(公告)日：2007-04-25
申请号：EP05759648.8
申请日：2005-07-12
IPC分类号： C07D475/00 , A61K31/519
CPC分类号： C07D475/00
摘要： The invention relates to novel 6-formyltetrahydropteridines of general formula (I), where the groups R1 to R6 have the meanings given in the claims and the description and the isomers thereof, method for production of said 6-formyltetrahydropteridines and use thereof as medicaments.
-
公开(公告)号：EP1765820A1
公开(公告)日：2007-03-28
申请号：EP05763510.4
申请日：2005-06-23
申请人： IRM LLC
发明人： REN, Pingda , WANG, Xia , GRAY, Nathanael Schiander , LIU, Yi , SIM, Taebo
IPC分类号： C07D475/00
CPC分类号： C07D475/00
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3, Flt3, GSK3β , IR, JNK1α 1, JNK2α 2, Lck, MKK4, MKK6, p70S6K, PDGFRα , Rsk1, SAPK2α , SAPK2β , Syk and Trkβ kinases.
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及Abl，Bcr-abl异常活化的疾病或病症的方法 ，Bmx，c-RAF，CSK，Fes，FGFR3，Flt3，GSK3β，IR，JNK1α1，JNK2α2，Lck，MKK4，MKK6，p70S6K，PDGFRα，Rsk1，SAPK2α，SAPK2β，Syk和Trkβ激酶。
-
9.发明公开NEUE 2-BENZYLAMINODIHYDROPTERIDINONE, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL 有权新的2 BENZYLAMINODIHYDROPTERIDINONE，方法及其及其作为药物
公开(公告)号：EP1761536A1
公开(公告)日：2007-03-14
申请号：EP05751714.6
申请日：2005-06-15
发明人： HOFFMANN, Matthias , STEEGMAIER, Martin , GRAUERT, Matthias , LEHMANN-LINTZ, Thorsten , REDEMANN, Norbert , SOLCA, Flavio
IPC分类号： C07D475/00 , A61K31/519 , A61P35/00
CPC分类号： C07D475/00
摘要： The invention relates to the novel 2-benzylaminodihydropteridinones of general formula (I), wherein the groups R1 to R7, R10 and R11 are defined as in the claims and in the description, and to the isomers thereof. The invention also relates to a method for producing said dihydropteridinones and to their use as drugs.
-
10.发明公开CHARGE TRANSPORT COMPOSITIONS AND ELECTRONIC DEVICES MADE WITH SUCH COMPOSITIONS 审中-公开电荷传输材料，从而生产电子元件
公开(公告)号：EP1532209A2
公开(公告)日：2005-05-25
申请号：EP03763459.9
申请日：2003-07-09
CPC分类号： C07D241/42 , C07C211/49 , C07C211/52 , C07C211/54 , C07C215/74 , C07C217/80 , C07C255/58 , C07D209/86 , C07D213/38 , C07D241/38 , C07D401/04 , C07D401/14 , C07D403/04 , C07D409/04 , C07D409/14 , C07D471/04 , C07D471/14 , C07D475/00 , C07D487/04 , C07F7/0852 , C08G61/122 , C08G61/124 , C08L65/00 , C09B11/10 , C09K11/06 , C09K2211/1044 , C09K2211/185 , H01L51/0035 , H01L51/0043 , H01L51/005 , H01L51/0059 , H01L51/0062 , H01L51/0065 , H01L51/0067 , H01L51/0068 , H01L51/0071 , H01L51/0072 , H01L51/0081 , H01L51/0085 , H01L51/0094 , H01L51/50 , H01L51/5012 , H01L51/5016 , H01L51/5048 , H01L2251/308 , H05B33/14 , Y10S428/917
摘要： The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.
-
-
-
-
-
-
-
-
-
搜索结果
113 条记录 (耗时 0.019 秒)
